Table S2.
The contribution of single, psychological factors to associations between beliefs about medication and CQR non-adherence (corrected for demographic and clinical factors)
| CQR non-adherence, OR (95% CI)
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|
| Necessity beliefs | Concern beliefs | NC differential | Overuse beliefs | Harm beliefs | Attitudinal profiles
|
||||
| Skeptical | Indifferent | Ambivalent | Accepting | ||||||
| Basic, adjusted model (including demographic and clinical variables)* | 0.8 (0.8–0.9)# |
1.0 (0.9–1.1) |
0.9 (0.9–1.0)# |
1.1 (1.0–1.2)‡ |
1.1 (1.0–1.2) |
1.8 (0.5–5.9) |
5.0 (1.3–19.3)‡ |
0.8 (0.5–1.4) |
0.9 (0.5–1.5) |
| + ICQ helplessness§ | – | – | – | – | – | – | – | 0.9 (0.5–1.6) |
0.8 (0.5–1.3) |
| + ICQ acceptance|| | – | – | – | – | – | – | – | 0.6 (0.4–1.1) |
1.1 (0.6–1.9) |
| + ICQ perceived benefits | – | – | – | – | – | – | 6.9 (1.5–32.2)‡ |
0.7 (0.4–1.2) |
1.0 (0.6–1.6) |
| + UVR self-efficacy pain | – | – | – | – | – | – | – | – | – |
| + UVR self-efficacy physical functioning | – | – | – | – | – | – | – | – | – |
| + UVR self-efficacy symptoms | – | – | – | – | – | – | – | – | – |
| + HADS anxiety/depression | – | – | – | – | – | – | – | – | – |
Notes:
Each of these models is adjusted for age, sex, living with others (yes/no), high education (yes/no), currently employed or studying (yes/no), disease duration, n DMARDs used, route of DMARD administration, disease activity (RADAI) and pain (VAS).
P≤0.01.
P≤0.05.
Basic, adjusted model (corrected for demographic and clinical variables) and ICQ helplessness.
Basic, adjusted model (corrected for demographic and clinical variables) and ICQ acceptance (etc). Data are shown as CQR non-adherence, OR (95% CI).
Abbreviations: CQR, Compliance Questionnaire Rheumatology; OR, odds ratio; NC, necessity concerns; ICQ, Illness Cognition Questionnaire; UVR, Arthritis Self-Efficacy Scale; HADS, Hospital Anxiety and Depression Scale; RADAI, Rheumatoid Arthritis Disease Activity Index; VAS, Visual Analog Scale; n DMARDs, number of disease-modifying antirheumatic drugs.